Elotuzumab

Elotuzumab Brand Name– Empliciti

What is Elotuzumab

Elotuzumab is a humanized IgG1 monoclonal antibody that specifically targets the Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) protein, which is present on myeloma cells and natural killer cells.

It is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received 1 to 3 prior therapies or in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.

Severe and fatal infection has been reported with elotuzumab therapy; monitor patients and treat infection promptly.

Indications

  • multiple myeloma

For the treatment of multiple myeloma

NOTE: The FDA has designated elotuzumab as an orphan drug for the treatment of multiple myeloma.

for the treatment of multiple myeloma in patients who have received 1 to 3 prior therapies, in combination with lenalidomide and dexamethasone

Side Effects

  1. anemia
  2. anorexia
  3. antibody formation
  4. asthenia
  5. bone pain
  6. bradycardia
  7. cataracts
  8. chest pain (unspecified)
  9. chills
  10. constipation
  11. cough
  12. diarrhea
  13. dyspnea
  14. elevated hepatic enzymes
  15. fatigue
  16. fever
  17. headache
  18. hepatotoxicity
  19. hyperbilirubinemia
  20. hyperglycemia
  21. hyperkalemia
  22. hypertension
  23. hypoalbuminemia
  24. hypocalcemia
  25. hypoesthesia
  26. hyponatremia
  27. hypotension
  28. infection
  29. influenza
  30. infusion-related reactions
  31. leukopenia
  32. lymphopenia
  33. metabolic acidosis
  34. muscle cramps
  35. new primary malignancy
  36. night sweats
  37. peripheral edema
  38. peripheral neuropathy
  39. pharyngitis
  40. pulmonary embolism
  41. renal failure (unspecified)
  42. thrombocytopenia
  43. vomiting
  44. weight loss

Monitoring Parameters

  • LFTs

Contraindications

  • breast-feeding
  • hepatic disease
  • hepatotoxicity
  • infection
  • infusion-related reactions
  • laboratory test interference
  • new primary malignancy
  • pregnancy

Interactions

  • Palifermin
  • Penicillamine
  • Tuberculin Purified Protein Derivative, PPD
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856